rediff.com
REAL-TIME QUOTE
Enter Company or MF
e.g. Tata motors, Reliance MF, 500570
SUN PHARMA ADVANCED RESEARCH COMPANY LTD. - Return Of Product Rights By Partner For ELEPSIA" XR 1000/1500 Mg
Download announcement < Back
15 Feb 2019
Pursuant to regulation 30 of the SEBI (Listing Obligation &amp; Disclosure Requirements) Regulations, 2015, we inform that we have received a communication from Sun Pharma Global FZE (SPGFZE), a wholly owned subsidiary of Sun Pharmaceutical Industries Limited, informing us that SPGFZE is not planning to launch ElepsiaTM XR (Levetiracetam Extended-Release Tablets) as CNS is not its focussed therapeutic area in US market, and therefore SPGFZE has decided to return the product rights back to SPARC.&lt;BR&gt; SPARC had out-licensed ELEPSIATM XR to SPGFZE in July 2016; and was eligible for sales linked milestone and royalties upon commercialization of Elepsia TM XR.&lt;BR&gt; Consequently, SPARC would find another partner for commercialising the captioned product.
View all announcements for SUN PHARMA ADVANCED RESEARCH COMPANY LTD. Source: BSE India